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Antibody drug conjugates (ADCs) are an emerging class of biopharmaceutical drug 
designed to treat cancer. They are comprised of monoclonal antibodies (mAbs) which are 
conjugated (linked) to potent drugs. The monoclonal antibodies provide high levels of 
specificity and are responsible for identifying and binding to antigens present on cancerous 
cells. After binding, antibody drug conjugate complexes are internalized by the cell. Once 
inside, the drug is released and the cell is killed. Thus, antibody drug conjugates are 
designed to kill only cancerous cells, leaving healthy tissue largely unaffected. This is very 
different from traditional chemotherapy methods that non discriminately kill both rapidly 
dividing cancerous and healthy cells causing many side effects. 
 
Currently, the synthesis of antibody drug conjugates requires many steps and is 
time consuming. For the purposes of this project, we focused on one specific synthesis step 
in the process called dialysis. During the synthesis process, the mAb must be reduced using 
a small molecule called Tris(2carboxyethyl)phosphine hydrochloride (TCEP). After 
reduction, TCEP is no longer necessary, but still in solution with the mAb. In order to 
successfully make antibody drug conjugates, this TCEP must be separated from the mAb. 
The current process to do this on a laboratory scale setting is called dialysis. Dialysis 
exploits the size difference between TCEP and mAb to achieve separation. We have 
identified this as one of the longest steps in the synthesis process. 
 
We hypothesized that we can use column chromatography in flow through mode as 
an alternative method to separate TCEP from mAb – TCEP mixtures. This method also 
exploits the size difference between TCEP and mAb to achieve separation. We tested 
microporous resins that allow small molecules like TCEP, but not large molecules like mAb 
to enter the pores. After identifying top performing resins, we went through the ADC 
synthesis process but implemented chromatography instead of dialysis. We concluded 
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Antibody drug conjugates (ADCs) are an important class of cancer therapeutic. 
These molecules are made up of three components, a monoclonal antibody (mAb), a drug 
and a linker.1 They have a highly specific mechanism of action, and are designed so that 
treatment is localized at the site of the tumor, while healthy tissue is largely unaffected. 
This is very different from the current standard of non selective chemotherapy, which 
kills rapidly dividing cells, regardless of whether they are cancerous or not. 
 
 
Currently, the synthesis of antibody drug conjugates is a lengthy multi – step 
process. In this project, we focused on one step of the process called dialysis. This step 
is used to purify and separate the mAb from a small molecule called 
Tris(2carboxyethyl)phosphine hydrochloride (TCEP) and is necessary for optimal ADC 
synthesis. Our project investigates whether an alternative, more efficient method called 
column chromatography in flow through mode can achieve comparable results. 
 
 
Antibody Drug Conjugates  
 
 
Antibody drug conjugates are comprised 
of three components, a monoclonal antibody 
(mAb), a drug and a linker.1 (Figure 1) The mAb 
is responsible for finding and binding to specific 
antigens expressed on cancer cells. The drug is a 
cytotoxic agent designed to kill cancer cells. 
Finally, the linker is responsible for attaching 





Figure 1: Antibody drug conjugate structure:  












Antibody drug conjugates are designed to kill cancer cells specifically at tumor sites. 
Initially, ADC’s are released into the body and circulate until mAbs identify and bind to an 
antigen receptor expressed on a cancer cell.3 (Figure 2) After binding, the ADC complex 
undergoes receptor – mediated endocytosis and enters the cell. Once inside the cell, the 
antibody and linker are degraded by the lysosome. Concurrently, the drug is released into 
the cell and causes cell death. Other cancer cells in the vicinity may also be killed through a 
process called the bystander effect.4 The mechanism of cancer cell death is dependent on 
drug type. There are two very prevalent types of drug.5 The first blocks tubulin assembly, 































This project involves a class of ADCs known as a site – specific antibody drug 
conjugates. With this type of ADC, drug load and conjugation site are specified. During the 
synthesis process, a cysteine is engineered into the mAb. 7 This cysteine is capped with 
 
2 
glutathione via a disulfide bond during expression. However, we need to attach the mAb to 
the linker and drug at this engineered cysteine site. Thus, the glutathione cap must be 























Currently, reduction is performed using a small 
molecule called Tris(2carboxyethyl)phosphine 
hydrochloride (TCEP). (Figure 4) The purpose of 
reduction is to remove the glutathione cap from 
cysteine. This is done by reducing disulfide bonds and 
introducing free thiol groups.7 (Figure 5) The 
 
antibody is then attached to the linker and drug at Figure 4: TCEP structure 8 

















However, after reduction, TCEP is no longer necessary, but still in solution with the 
mAb. In the subsequent synthesis steps, the presence of TCEP causes unwanted side 
 
3 
reactions and results in lower conjugation efficiency. Thus, it is important to remove TCEP 




Dialysis removes TCEP from the sample and also dilutes it with buffer. For 
example, it is common for mAb concentration to go from 10 mg/ml to 5 mg/ml during this 
process. To get back to the initial concentration we have to concentrate the sample. After 
this, the mAb undergoes reoxidation of disulfide bridges. In the previous reduction step, 
TCEP is used to reduce the disulfide bonds in the mAb to introduce free thiols. This is 
necessary at the engineered cysteine site where we want to connect the linker and drug to 
the mAb. However, in the process, other disulfide bonds in the mAb are also reduced 
(Figure 6). To reform these bonds, the mAb must undergo oxidation. After oxidation, the 
































Figure 6: ADC Synthesis: (A) antibody intermediate (B) antibody intermediate after reduction (C) antibody intermediate after 












For small scale synthesis of antibody drug conjugates, dialysis is used to remove 
TCEP from mAb-TCEP solutions. This separation method exploits the size difference 
between TCEP and mAbs. For reference, TCEP is 287 grams/mole while the mAb is 210,000 
grams/mole. Dialysis involves placing the mAb-TCEP sample in a semi – permeable dialysis 
membrane, which is then placed in buffer. The small TCEP molecules diffuse out of the 
membrane while the mAb remains inside and separation is achieved.10 
 
 
These dialysis membranes are characterized by their molecular-weight cutoff 
(MWCO). The MWCO is the smallest average molecular mass of a standard molecule that 
will not effectively diffuse across the membrane. For example, a membrane with a 3K 
MWCO generally retains >90% of a protein with a molecular mass of at least 3 kDA or 
 
3,000 grams/mol. Thus, we can use the molecular weights of TCEP and mAb to determine a 







We believe we can use column chromatography in flow through mode as an 
alternative method to separate TCEP from mAb-TCEP solutions. In this process, a 
chromatographic column is packed with a resin. This resin contains beads and these beads 
contain pores. For efficient separation, we require a resin with beads that will retain TCEP. 
Furthermore, the pores of these beads need to be small enough that the mAb cannot enter, 

































Figure 7: Separation using microporous resins (A) The mAb-TCEP sample is placed into a column filled with microporous 





We are primarily interested in microporous anion exchange resins. According to the 
manufacturer, these resins generally have a microporosity less than 30 Angstroms. 
Furthermore, these resins carry a positive charge. We believe that negatively charged TCEP 
molecules will bind to these resins at a high degree, while the mAb will not. Furthermore, we 
believe this process will take ~1 hour, which is substantially less than dialysis. 
 
 
Dynamic Binding Capacity (DBC) 
 
 
In order to achieve efficient separation, we must identify chromatographic resins 
that bind to TCEP but don’t bind to our mAb. We use dynamic binding capacity (DBC) to 
measure this property. This is the binding capacity under operating conditions (i.e. in 
column under specified conditions) and is defined as the amount of target molecule that 
binds to the medium (resin) under given flow conditions before a significant 
breakthrough of molecule occurs.13 For our process, we require a resin with a high binding 










Dynamic Binding Capacity of TCEP 
 
 
Initial experiments were carried out to test the dynamic binding capacity of TCEP 
on multiple resins. All experiments were carried out using an AKTA Pure, GE Healthcare. 
Uv-vis measurements on the AKTA Pure were taken at 195 nm. All experiments were 
performed using Omnifit columns, Diba Industries. All resins were manufactured by Dow 





For this experiment, the system was on bypass mode and the sample did not 
pass through a column. The method conditions and buffers are as follows: 
 
 
 Sample/Buffer Volume (mL) Flow rate (ml/min) 
    
Equilibration 20 mM Phosphate 10 2 
    
Sample Load 2 mM TCEP 10 2 
    
Equilibration 20 mM Phosphate 8 2 
























Amberlite FPX 66 
 
A 1.6 ml column was packed with Amberlite FPX 66 resin, a macroporous non-




 Sample/Buffer Column Volume Flow rate (ml/min) 
    
Equilibration 20 mM Phosphate 10 2 
    
Sample Load 2 mM TCEP 30 2 
    
Regeneration 2% Methanol 10 .5 
    
Column wash Water for injection (WFI) 5 .5  
 
*1 Column volume = 1.6 ml 
 
 
Similar experiments were performed using Amberlite FPA 98Cl, Amberlite XAD 7HP, 
and Dowex 1x4.15, 16, 17 Method conditions and buffers can be found in Appendix A. 
 
 
Dynamic Binding Capacity of TCEP Using Microporous Resins 
 
 
Further experiments were carried out to test the dynamic binding capacity of TCEP 
on microporous resins at multiple pH levels. All experiments were carried out using an 
AKTA Pure, GE Healthcare. Uv-vis measurements on the AKTA Pure were taken at 195 nm. 
All experiments were performed using Omnifit columns, Diba Industries. 
 
 
Dowex 1x4, Dowex 1x8 and Dowex Marathon A2 resin were manufactured by Dow 
Chemical.17. 18 Experiments with these resins were performed at pH 6, 6.5 and 7. Diaion 
SK1B resin was manufactured by Mitsubishi Chemical Corporation.19 Experiments with 
this resin were performed at pH 7. pH adjustments were made using 1M Tris and 6N HCl 









A 1.9 ml column was packed with Dowex 1x4 resin. The method conditions 




 Sample/Buffer Column Volume Flow rate (ml/min) 
    
Equilibration 20 mM Phosphate 10 2 
    
Sample Load 2 mM TCEP 5.32 2 
    
Equilibration 20 mM Phosphate 10 2 
    
Regeneration .1 N NaOH 5 1.31 
    
Column wash 20 mM Phosphate 5 .4  
 
*1 Column volume = 1.9 ml 
 
 
Method conditions and buffers for experiments using Dowex 1x8, Dowex Marathon 
A2 and Diaion SK1B can be found in Appendix B. 
 
 
Dynamic Binding Capacity of mAb1 
 
 
Experiments were carried out to test the dynamic binding capacity of mAb1 on 
microporous resins at multiple pH levels . All experiments were carried out using an 
AKTA Pure, GE Healthcare. Uv-vis measurements on the AKTA Pure were taken at 280 nm. 
All experiments were performed using Omnifit columns, Diba Industries. 
 
 
Experiments with Dowex 1x4, Dowex 1x8 and Dowex Marathon A2 resin were 
performed at pH 6, 6.5 and 7. The experiment with Diaion SK1B resin was performed at pH 
 
7. The control experiment was performed at pH 7. pH adjustments were made using 1M 








For this experiment, the system was on bypass mode and the sample did not 
pass through a column. The method conditions and buffers are as follows. 
 
 
 Sample/Buffer Volume (mL) Flow rate (ml/min) 
    
Equilibration 20 mM Phosphate 10 1.31 
    
Sample Load 5 mg/ml mAb1 2 .3 
    
Equilibration 20 mM Phosphate 10 1.31 






A 1.9 ml column was packed with Dowex 1x4. The method conditions and buffers 
are as follows. 
 
 
For pH 7 and 6.5  
 
 Sample/Buffer Column Volume Flow rate (ml/min) 
    
Equilibration 20 mM Phosphate 10 1.31 
    
Sample Load 5.66 mg/ml mAb1 1 .3 
    
Equilibration 20 mM Phosphate 10 1.31 
    
Regeneration .1 N NaOH 5 1.31 
    
Column Wash 20 mM Phosphate 5 1.31  
 











For pH 6  
 
 Sample/Buffer Column Volume Flow rate (ml/min) 
    
Equilibration 20 mM Phosphate 10 1.31 
    
Sample Load 4.53 mg/ml mAb1 1.2 .3 
    
Equilibration 20 mM Phosphate 10 1.31 
    
Regeneration .1 N NaOH 5 1.31 
    
Column Wash 20 mM Phosphate 5 1.31  
 
*1 Column volume = 1.9 ml 
 
 
Method conditions and buffers for experiments using Dowex 1x8, Dowex Marathon 
A2 and Diaion SK1B can be found in Appendix C. 
 
 
Dynamic Binding Capacity of TCEP-mAb1 Solution 
 
 
An experiment was carried out to test the dynamic binding capacity of a TCEP-
mAb1solution on Dowex 1x4 resin. This experiment was carried out using an AKTA Pure, 
GE Healthcare. Uv-vis measurements on the AKTA Pure were taken at 195 nm and 280 nm. 
This experiment was performed using an Omnifit column, Diba Industries packed with 1.9 
ml of resin. This experiment was run at pH 6.5 and pH adjustments were made with 1M 



















 Sample/Buffer Column Volume Flow rate (ml/min) 
    
Equilibration 20 mM Phosphate 10 1.31 
    
Sample Load 4.44 mg/ml mAb1, 2mM TCEP 1.2 .3 
    
Equilibration 20 mM Phosphate 10 1.31 
    
Regeneration .1 N NaOH 5 1.31 
    
Column Wash 20 mM Phosphate 5 1.31  
 






A final experiment synthesizing the antibody drug conjugate was performed to test 







A control experiment was performed using the current ADC synthesis method, as 
described below. A negative control experiment was also performed following the 
method described below. However, during the negative control, the sample did not 
undergo the dialysis and sample concentration steps. 
 
 
1. Antibody preparation 
 
mAb1 stock protein at 20 mg/ml was diluted to 10 mg/ml with 1X PBS, pH 7.2. Then the 














TCEP was added to the solution at 40 mole equivalents of TCEP to 1 mole of antibody. 
The pH was adjusted to 6.5 - 7 with 1M Tris buffer. After, the solution was stirred at 





The sample was filtered using a .2 um PES membrane, ThermoFisher Scientific and transferred to a 10K Slide-
A-Lyzer Dialysis Cassette, ThermoFisher Scientific . Then, the membrane was transferred to 1X PBS, pH 7.2 
buffer. The solution was stirred at 4 ℃ for three hours and then the membrane was transferred to new 
solution of 1X PBS, pH 7.2 buffer. This new solution was stirred at 4 ℃ overnight. 
 
 
4. Sample concentration 
 
The sample was removed from the membrane and filtered using a .2 um PES 
membrane, ThermoFisher Scientific. It was then concentrated to 10 mg/ml using 





DHAA was added to the solution at 20 mole equivalents of DHAA to 1 mole of antibody. 







DMSO was added to the solution at 10% of the conjugation volume. The payload 
was added to the solution at 7.5 mole equivalents of payload to 1 mole of antibody. 
The solution was stirred for one hour at room temperature. 
 
 
7. Quenching of conjugation 
 
N-acetyl Cysteine (NAc) was added to the solution at 4 mole equivalents of NAc to 1 mole 
of drug-linker. This solution was stirred for thirty minutes at room temperature. The 





Analysis of the sample was performed using reverse phase high performance liquid 
chromatography on an Agilent system. See Appendix D for method specifications. 
 
 
ADC Synthesis with Column Chromatography 
 
 
This experiment followed the same procedure as the control, however, the dialysis 
step was replaced with a column chromatography step. Method conditions and buffers 
for experiments with Dowex 1x4, Dowex 1x8, Dowex Marathon A2, Diaion SK1B and the 
control can be found in Appendix E. 
 
 
ADC Synthesis with Column Chromatography and no Sample Concentration 
 
 
Negative Control without sample concentration 
 
This experiment generally followed the same procedure as the control described 
above however there were three changes. 
 
1. In the sample preparation step mAb1 was diluted to 5 mg/ml 
 
2. The dialysis step was removed 
 
3. The sample concentration step was removed. 
 
 
Column chromatography without sample concentration 
 
This experiment generally followed the same procedure as the control described 
above however there were three changes. 
 
1. In the sample preparation step mAb1 was diluted to 5 mg/ml 
 
2. The dialysis step was replaced with a column chromatography step 
 
3. The sample concentration step was removed. 
 
Method conditions and buffers for experiments with Dowex 1x8, Dowex Marathon 












The results from the AKTA Pure and Agilent system came in the form of 
chromatograms. Data from the AKTA Pure indicated the dynamic binding capacity of TCEP, 




Dynamic Binding Capacity of TCEP 
 
 
Generally, a numerical amount of binding is determined by finding sample 
concentration using the Beer-Lambert Law, 
 
 
A = ɛCL, 
 
A = absorbance 
 
ɛ = molar extinction 
coefficient C = concentration 
 
L = path length 
 
 
However, in this case, the molar extinction coefficient of TCEP was unknown. As an 
alternative method of identifying whether TCEP was binding to the resins, we used the 
control experiment as a baseline. The control indicated the maximum absorbance increase 
of the system (UV detector) if no binding occurred. After adding 10 ml of 2 mM TCEP we 
found this value to be 500 mAU Thus, if the maximum absorbance increase of a resin is 













































Using the results from the control experiment, and Table 1, it is clear that Amberlite 
FPX66 and Amberlite XAD 7HP did not bind to TCEP. While the maximum absorbance 
increase using these resins was higher than the control, we assumed they were within the 
margin of error for this experiment. Amberlite FPA 98Cl bound to TCEP more tightly than 
Amberlite FPX66 and Amberlite FPA 98Cl, however, the binding was still not considered 
strong. Dowex 1x4 resin outperformed all other resins and bound tightly to TCEP. 
 
 
Table 1: Maximum Absorbance Increase of Amberlite and Dowex Resins (TCEP)   
 
Maximum Absorbance Increase 
Amount of 2 mM TCEP added 
Resin to reach maximum 
 (mAU) 
absorbance increase (ml)   
   
Amberlite FPX 66 575 13 
   
Amberlite FPA 98Cl 275 24 
   
Amberlite XAD 7HP 550 13 
   
Dowex 1x4 80 47 
    
* See Appendix G for these results in chromatogram form 
16 
Dynamic Binding Capacity of TCEP Using Microporous Resins 
 
 
For this experiment, the dynamic binding capacity of TCEP with Dowex 1x4, 
Dowex 1x8, Dowex Marathon A2 and Diaion SK1B was tested. 10 ml of 2 mM TCEP was 
added to each resin. Similarly to the previous experiment, these results were compared to 
the control to determine whether TCEP bound. 
 
 
At pH 7, Dowex 1x8 appeared to bind the tightest to TCEP followed by Dowex 1x4 
and then Dowex Marathon A2. (Table 2) The same pattern followed for pH 6.5. At pH 6 
Dowex Marathon A2 appeared to have the strongest binding to TCEP while Dowex 1x4 and 
Dowex 1x8 were tied. However, once again, there was a margin of error for these 
experiments and a definitive ranking could not be made. Ultimately, the take away from 
this is that all three resins tested bound tightly to TCEP at pH 7, 6.5 and 6. 
 
 
At pH 7, the maximum absorbance increase of Diaion SK1B was 450 mAU. While 
this was lower than the control result of 500 mAU, we assumed it was within the margin of 
error and concluded Diaion SK1B did not bind to TCEP. 
 
Table 2: Maximum Absorbance Increase of Dowex and Diaion Resins (TCEP) 
 
 Resin pH  Maximum Absorbance Increase (mAU) 
     
 Dowex 1x4 7  100 
     
  6.5  70 
     
  6  60 
     
 Dowex 1x8 7  75 
     
  6.5  25 
     
  6  60 
     
 Dowex Marathon A2 7  125 
     
  6.5  110 
     
  6  40 
     
 Diaion SK1B 7  450 
    
 *See Appendix H for these results in chromatogram form 
   17 
Dynamic Binding Capacity of mAb1 
 
 
To ensure separation of TCEP and mAb1, TCEP must bind to the resin in the column, 
while mAb1 flows through. For this experiment, we determined the dynamic binding 
capacity of mAb1 using the microporous resins. Once again, a control was used to 
determine the maximum absorbance increase of the system (UV detector) after adding 10 



































For this experiment, 10 mg of mAb1 was added to four separate columns with 
Dowex 1x4, Dowex 1x8, Dowex Marathon A2 and Diaion SK1B. The protein did not bind to 
the Dowex resins at pH 7, 6.5 or 6. (Table 3) Similarly, it also did not bind to Diaion SK1B 
at pH 7. While the maximum absorbance increase did not always reach 900 mAU, the 








Table 3: Maximum Absorbance Increase of Dowex and Diaion Resins (mAb1)  
 
Resin pH Maximum Absorbance Increase (mAU) 
   
Dowex 1x4 7 850 
   
 6.5 900 
   
 6 825 
   
Dowex 1x8 7 825 
   
 6.5 825 
   
 6 825 
   
Dowex Marathon A2 7 850 
   
 6.5 875 
   
 6 800 
   
Diaion SK1B 7 825  
 
*See Appendix I for these results in chromatogram form 
 
 
Dynamic Binding Capacity of mAb1-TCEP Solution 
 
 
Results from the previous experiments indicated that TCEP bound to Dowex 1x4, 
Dowex 1x8 and Dowex Marathon A2 but mAb1 did not. In order to make sure this 
remained true when TCEP and mAb1 were combined and mimic true conditions, we mixed 




The wavelength of 280 nm was used to test the dynamic binding capacity of mAb1, 
while 195 nm was used to test the dynamic binding capacity of TCEP. At 280 nm the 
maximum absorbance increase of the mAb1-TCEP solution was 800 mAU. After comparing 
it to the control from the previous mAb1 experiment, we concluded that mAb1 did not bind 
to Dowex 1x4 resin. At 195 nm the maximum absorbance increase of the mAb1-TCEP 
solution was 2150 mAU. This was much different from the control of the TCEP experiment 





was also being detected at 195 nm so we could not conclude whether TCEP was binding 

































In order to test whether column chromatography using microporous resins was a 
feasible alternative to dialysis we had to go through the ADC synthesis process described 
in the methods section. The steps included sample preparation, reduction, dialysis or 
column chromatography, oxidation, conjugation, quenching of conjugation and analysis. 
 
We first performed a control experiment and negative control. The control used the 
current ADC synthesis method, and resulted in successful conjugation. The negative control 
used the current ADC synthesis method without the dialysis step, and resulted in failed 
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ADC Synthesis with Column Chromatography 
 
 
After the control, we performed another experiment following the current ADC 
synthesis method but implementing column chromatography instead of dialysis. These 
experiments were performed using Dowex 1x4, Dowex 1x8, Dowex Marathon A2 and Diaion 
SK1B. We compared these chromatograms to the control and negative control to determine 
whether conjugation was successful or not. For example, the results with Dowex 1x4 looked 




The same was true for experiments with Dowex 1x8, Dowex Marathon A2 and Diaion SK1B. 
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ADC Synthesis with Column Chromatography and no Sample Concentration 
 
 
We first performed a negative control*. This experiment followed the same 
procedure as the control experiment described in the previous section but we removed 
the dialysis and sample concentration steps. We compared this chromatogram to the one 
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After the control, we performed another experiment following the current ADC 
synthesis method but implementing column chromatography instead of dialysis and 
removing the sample concentration step. These experiments were performed using Dowex 
1x8, Dowex Marathon A2 and Diaion SK1B. We compared these chromatograms to the 
control and negative control* to determine whether conjugation was successful or not. The 
results with Dowex Marathon A2 looked similar to the control, so we concluded synthesis 
was successful. (Figure 15) The same was true for the experiment with Diaion SK1B. The 
result using Dowex 1x8 looked similar to the negative control* so we concluded ADC 
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The goal of this project was to implement column chromatography in flow 
through for the removal of TCEP using microporous resins. In order to do this, we first 
tested the dynamic binding capacity of TCEP. After selecting top performing resins, we 
tested the dynamic binding capacity of mAb1. Next, we tested the dynamic binding 
capacity of a mAb1-TCEP mixture. Finally, we performed antibody drug conjugate 
synthesis while implementing column chromatography instead of dialysis. 
 
 
Dynamic Binding Capacity of TCEP 
 
 
We started by testing a variety of resins for their ability to bind to TCEP. The first 
resin we tested was Amberlite FPX66. This is a macroporous adsorbent with an aromatic 
polymer backbone. We found that this resin did not bind to TCEP, most likely because it’s 
comprised of a hydrophobic backbone. Amberlite XAD 7HP, another macroporous resin 
also did not bind to TCEP. This resin is moderately polar, with an acrylic resin backbone. Its 
main uses are to remove non polar compounds from aqueous solutions and slightly polar 
compounds from non-polar solvents. However, our TCEP solution did not meet these 
conditions, thus the resin was unable to adsorb and remove TCEP. 
 
 
Amberlite FPA 98Cl resin, is a macroporous strong base anion exchanger and did 
show some binding capacity to TCEP. This makes sense because the TCEP solution was 
negatively charged. Dowex 1x4 resin showed the largest amount of TCEP binding. Like 
Amberlite FPA 98Cl, Dowex 1x4 is also a strong base anion exchanger. This resin is 
classified as a microporous resin, while Amberlite FPA 98Cl is a macroporous resin. Dowex 











Dynamic Binding of TCEP Using Microporous Resins 
 
 
After identifying Dowex 1x4 as the resin with the highest TCEP binding capacity, 
we wanted to test the dynamic binding capacity of other similar resins. We chose Dowex 
1x8 and Dowex Marathon A2, which are both micrporous strong anion exchangers. As a 




At pH 7, 6.5 and 6 TCEP is expected to have a negative charge. This agrees with our 
results because TCEP was able to bind to Dowex 1x4, Dowex 1x8 and Dowex Marathon A2, 
which have positively charged functional groups. Conversely, it was not able to bind to 
Diaion SK1B resin, which has a negatively charged functional group. 
 
 
Generally, as the pH of the TCEP solution was lowered, the binding capacity 
increased. Overall, for the anion exchange resins, it was clear that there was substantial 
binding at all pH levels. 
 
 
Dynamic Binding Capacity of mAb1 
 
 
From the previous experiments, we determined that TCEP could bind to charged 
microporous resins. To ensure separation, it was essential that our protein did not bind to 
these resins. Consequently, we determined the dynamic binding capacity of mAb1 using 
Dowex 1x4, Dowex 1x8, Dowex Marathon A2 and Diaion SK1B. 
 
 
At pH 7, 6.5 and 6 mAb1 is expected to have a positive charge. This agrees with our 
results because mAb1 did not bind to Dowex 1x4, Dowex 1x8 and Dowex Marathon A2, 
which have positively charged functional groups. It also was not able to bind to Diaion 
SK1B resin, even though it has a negatively charged functional group. This is because 






Dynamic Binding Capacity of mAb1-TCEP Solution 
 
 
Based on the experiments completed so far, TCEP appeared to bind to the 
negatively charged microporous resins while mAb1 did not. We combined TCEP and mAb1 
into a solution to mimic true conditions. This also allowed us to test whether the previous 
results still held true after the two components were mixed. 
 
 
We performed this experiment at pH 6.5 and used Dowex 1x4 resin. At this pH level 
TCEP is expected to be negatively charged while mAb1 is expected to be positively charged. 
At 280 nm, the wavelength used to measure proteins, we saw that mAb1 did not bind to the 
resin while in solution. At 195 nm, the wavelength used to measure TCEP, we could not 
determine whether TCEP was binding. We found that protein was also absorbed at 195 nm, 
so the reading we got was of the mAb1-TCEP solution. However, we hypothesized that 
TCEP was still binding. 
 
 
ADC Synthesis using Column Chromatography 
 
 
In order to determine whether column chromatography could separate TCEP and 
mAb1 we performed ADC synthesis. For our control, we followed the current conjugation 
method to demonstrate successful synthesis. For our negative control, we also used the 
current conjugation method but removed the dialysis step. This showed us what an 
unsuccessful synthesis looks like. Using RPHPLC, we compared the difference in 
successful vs unsuccessful synthesis chromatograms. 
 
 
We then tested our new method; this followed the current synthesis method but 
replaced the dialysis step with column chromatography. We achieved successful synthesis 
using Dowex 1x4, Dowex 1x8, Dowex Marathon A2 and Diaion SK1B. Based on the results 
of our previous experiments, we expected this method to work with the Dowex resins. 
However, in past experiments, Diaion SK1B did not bind to TCEP. We hypothesized that the 




ADC Synthesis with Column Chromatography and no Sample Concentration 
 
 
We performed another ADC synthesis experiment to test whether the 
sample concentration step caused the successful results while using Diaion SK1B. 
First we performed another negative control*, following the current synthesis 
method while removing the dialysis and sample concentration steps. This showed 
us what an unsuccessful conjugation looks like. 
 
 
We then tested our new method; this followed the current synthesis method but 
replaced the dialysis step with column chromatography and removed the sample 
concentration step. We achieved successful synthesis using Dowex Marathon A2 and 
Diaion SK1B. Synthesis was unsuccessful using Dowex 1x8 resin. These results did not 
align with our hypothesis. We expected positive results with Dowex Marathon A2 and 
Dowex 1x8, but negative results with Diaion SK1B. The most probable explanation for 
these results is human error. There’s a possibility that the Dowex 1x8 and Diaion SK1B 
resins were switched or mislabeled somewhere in the process. However, due to time 
constraints we were unable to repeat this experiment. 
 
 
Further experiments are needed to determine the cause of this discrepancy. 
These experiments should be repeated in triplicate. Furthermore, experiments using this 
procedure should be performed using Dowex 1x4. Regardless of this variability, we have 






Overall, this project proved that TCEP removal using column chromatography in 
flow through mode is possible. Our first experiment helped us identify resins with a 
strong binding capacity to TCEP. Next, we performed experiments to ensure these resins 
did not also bind to mAb1. Finally, we performed antibody drug conjugate synthesis to 




chromatography, we demonstrated this method is a promising alternative to dialysis. This 
will be particularly interesting for high-throughput conjugation screening applications, as it 
allows a rapid intermediate buffer exchange after the reduction step. As discussed in the 





























































1. Dimasi N., Fleming R., Zhong H., Bezabeh B., Kinneer K., Christie R., Fazenbaker C., Wu 
H, and Gao C., Efficient Preparation of Site-Specific Antibody–Drug Conjugates Using 
Cysteine Insertion. Molecular Pharmaceutics, 2017 14 (5), 1501-1516, doi:  
10.1021/acs.molpharmaceut.6b00995 
 
2. This photo was obtained with permission from an employee at Medimmune. 
 
3. Panowski, S., Bhakta, S., Raab, H., Polakis, P., & Junutula, J. R. Site-specific Antibody Drug 
Conjugates for Cancer Therapy. mAbs, 2014, 6(1), 34–45, doi: 10.4161/mabs.27022 
 
4. Staudacher A. Antibody Drug Conjugates and Bystander Killing: Is Antigen 
Dependent Internalisation Required. British Journal of Cancer, 2017, 117, 1736 -174, 
doi:10.1038/bjc.2017.367 
 
5. Chalouni C, Doll S. Fate of Antibody-Drug Conjugates in Cancer Cells. Journal of 
Experimental & Clinical Cancer Research, 2018, 37(20), doi:10.1186/s13046-017-
0667-1. 
 
6. Carter PJ., Senter PD., Antibody-Drug Conjugates for Cancer Therapy. The Cancer Journal 
2008. 14 (3), 154 – 169, doi: 10.1097/PPO.0b013e318172d704. Image reprinted with 
permission 
 
7. Zhou Q. Site-Specific Antibody Conjugation for ADC and Beyond. Biomedicines, 2017, 
5(4), 64, doi:10.3390/biomedicines5040064 
 




9. This image was obtained from http://www.biosyn.com/tew/instruction-of-
reduction-reaction-using-tcep.aspx 
 




11. Walch N., Jungbauer A., Continuous Desalting of Refolded Protein Solution Improves 
Capturing in Ion Exchange Chromatography: A Seamless Process. Biotechnology Journal 
2017, 12(6), doi 10.1002/biot.201700082 
 
12. This image was obtained from http://technologyinscience.blogspot.com/2011/09/gel-
filtration-chromatography-gf-size.html 
 








































































Amberlite FPA 98Cl 
 
A 1.2 ml column was packed with FPA 98 Cl resin, a macroporous strong 




 Sample/Buffer Column Volume Flow rate (ml/min) 
    
Equilibration 20 mM Phosphate 10 2 
    
Sample Load 2 mM TCEP 20 2 
    
Regeneration 10% NaCl, 4% NaOH 10 .3 
    
Column wash Water for injection (WFI) 10 .5  
 
*1 Column volume = 1.2 ml 
 
 
Amberlite XAD 7HP 
 
A 1.4 ml column was packed with Amberlite XAD 7HP resin, a macroporous 




 Sample/Buffer Column Volume Flow rate (ml/min) 
    
Equilibration 20 mM Phosphate 10 2 
    
Sample Load 2 mM TCEP 30 2 
    
Regeneration .1 N NaOH 10 .5 
    
Column wash Water for injection (WFI) 10 .5  
 









A 1.9 ml column was packed with Dowex 1x4 resin, a microporous strong 




 Sample/Buffer Column Volume Flow rate (ml/min) 
    
Equilibration 20 mM Phosphate 10 2 
    
Sample Load 2 mM TCEP 25 2 
    
Elution 1M NaCl 15 2 
    
Regeneration 10% NaCl, 4% NaOH 15 .5 
    
Column wash Water for injection (WFI) 10 .4  
 






































Appendix B: Methods - Dynamic Binding Capacity of TCEP 





A 1.4 ml column was packed with Dowex 1x8 resin, a microporous strong 




 Sample/Buffer Column Volume Flow rate (ml/min) 
    
Equilibration 20 mM Phosphate 10 2 
    
Sample Load 2 mM TCEP 7.09 2 
    
Equilibration 20 mM Phosphate 10 2 
    
Regeneration .1 N NaOH 5 1.31 
 
*1 Column volume = 1.4 ml 
 
 
Dowex Marathon A2 
 
A 1.5 ml column was packed with Dowex Marathon A2 resin, a microporous 
strong anion exchanger. The method conditions and buffers are as follows. 
  Sample/Buffer Column Volume Flow rate (ml/min) 
     
 Equilibration 20 mM Phosphate 10 2 
     
 Sample Load 2 mM TCEP 6.71 2 
     
 Equilibration 20 mM Phosphate 10 2 
     
 Regeneration 1 N NaOH 5 1.31 
     
 Column wash 20 mM Phosphate 5 .4 
     
 *1 Column volume = 1.5 ml   





A 1.4 ml column was packed with Diaion SK1B resin, a microporous strong cation 




 Sample/Buffer Column Volume Flow rate (ml/min) 
    
Equilibration 20 mM Phosphate 10 2 
    
Sample Load 2 mM TCEP 7.09 2 
    
Equilibration 20 mM Phosphate 10 2 
    
Regeneration 2 M HCl 5 1.31  
 












































A 1.4 ml column was packed with Dowex 1x8 resin. The method conditions and 




 Sample/Buffer Column Volume Flow rate (ml/min) 
    
Equilibration 20 mM Phosphate 10 1.31 
    
Sample Load 4.62 mg/ml mAb1 1.53 .3 
    
Equilibration 20 mM Phosphate 10 1.31 
    
Regeneration .1 N NaOH 5 1.31  
 
*1 Column volume = 1.4 ml 
 
 
Dowex Marathon A2 
 
A 1.5 ml column was packed with Dowex Marathon A2 resin. The method 
conditions and buffers are as follows. 
 
 
For pH 7 and 6 
 
  Sample/Buffer Column Volume Flow rate (ml/min) 
     
 Equilibration 20 mM Phosphate 10 1.31 
     
 Sample Load 4.53 mg/ml mAb1 1.5 .3 
     
 Equilibration 20 mM Phosphate 10 1.31 
     
 Regeneration 1 N NaOH 5 1.31 
     
 Column Wash 20 mM Phosphate 5 1.31 
     
 *1 Column volume = 1.5 ml   
   35  
For pH 6.5  
 
 Sample/Buffer Column Volume Flow rate (ml/min) 
    
Equilibration 20 mM Phosphate 10 1.31 
    
Sample Load 5.66 mg/ml mAb1 1.3 .3 
    
Equilibration 20 mM Phosphate 10 1.31 
    
Regeneration 1 N NaOH 5 1.31 
    
Column Wash 20 mM Phosphate 5 1.31  
 





A 1.4 ml column was packed with Diaion SK1B resin. The method conditions 




 Sample/Buffer Column Volume Flow rate (ml/min) 
    
Equilibration 20 mM Phosphate 10 1.31 
    
Sample Load 4.62 mg/ml mAb1 1.53 .3 
    
Equilibration 20 mM Phosphate 10 1.31 
    
Regeneration 2 M HCl 5 1.31  
 



















Time (min) %A %B 
 (Water + Trifluoroacetic Acid) (Acetonitrile + Trifluoroacetic Acid) 
   
0 80 20 
   
3 80 20 
   
20 60 40 
   
22 5 95 
   
26 5 95 
   
30 80 20 











































  Sample/Buffer Column Volume Flow rate (ml/min) 
     
 Equilibration 20 mM Phosphate 10 1.31 
     
 Sample Load 5.49 mg/ml mAb1 1.35 .26 
     
 Equilibration 20 mM Phosphate 10 1.31 
     
 Regeneration .1 N NaOH 5 1.31 
     
 *1 Column volume = 1.8 ml   
Dowex 1x8    
     
  Sample/Buffer Column Volume Flow rate (ml/min) 
     
 Equilibration 20 mM Phosphate 10 1.31 
     
 Sample Load 9.38 mg/ml mAb1 1 .26 
     
 Equilibration 20 mM Phosphate 10 1.31 
     
 Regeneration .1 N NaOH 5 1.31  
 




















Dowex Marathon A2 
 
  Sample/Buffer Column Volume Flow rate (ml/min) 
     
 Equilibration 20 mM Phosphate 10 1.31 
     
 Sample Load 5.39 mg/ml mAb1 1.8 .26 
     
 Equilibration 20 mM Phosphate 10 1.31 
     
 Regeneration 1 N NaOH 5 1.31 
     
 *1 Column volume = 1.7 ml   
Diaion SK1B    
     
  Sample/Buffer Column Volume Flow rate (ml/min) 
     
 Equilibration 20 mM Phosphate 10 1.31 
     
 Sample Load 5.39 mg/ml mAb1 1.75 .26 
     
 Equilibration 20 mM Phosphate 10 1.31 
     
 Regeneration 2 M HCl 5 1.31  
 

























Appendix F: Methods - ADC Synthesis with Column Chromatography and 





  Sample/Buffer Column Volume Flow rate (ml/min) 
     
 Equilibration 20 mM Phosphate 10 1.31 
     
 Sample Load 10.25 mg/ml mAb1 1 .26 
     
 Equilibration 20 mM Phosphate 10 1.31 
     
 Regeneration .1 N NaOH 5 1.31 
     
 *1 Column volume = 1.3 ml   
Dowex Marathon A2   
     
  Sample/Buffer Column Volume Flow rate (ml/min) 
     
 Equilibration 20 mM Phosphate 10 1.31 
     
 Sample Load 10.25 mg/ml mAb1 1 .26 
     
 Equilibration 20 mM Phosphate 10 1.31 
     
 Regeneration 1 N NaOH 5 1.31  
 

















Diaion SK1B  
 
 Sample/Buffer Column Volume Flow rate (ml/min) 
    
Equilibration 20 mM Phosphate 10 1.31 
    
Sample Load 10.25 mg/ml mAb1 1 .26 
    
Equilibration 20 mM Phosphate 10 1.31 
    
Regeneration 2 M HCl 5 1.31  
 













































































































































































































Figure 20: Chromatogram of TCEP, Dowex 1x4, pH 6, 6.5, 7, maximum absorbance increase of 60, 70 and 100 





























































































































Figure 24: Chromatogram of mAb1, Dowex 1x4, pH 6, 6.5, 7, maximum absorbance increase of 825, 900 and 850 


























































Figure 26: Chromatogram of mAb1, Dowex Marathon A2, pH 6, 6.5, 7, maximum absorbance increase of 800, 875 and 
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Appendix K: Results – ADC Synthesis with Column Chromatography and 






















8 10 12 14 16 18 20 min 
 




















8 10 12 14 16 18 20 min 
 




















3905 Canterbury Rd Baltimore, MD 21218 | 646-875-9375 | salpers1@jhu.edu 
 
Education  
M.S. Chemical and Biomolecular Engineering | May 2018 | Johns Hopkins University 
B.S. Chemical and Biomolecular Engineering | May 2017 | Johns Hopkins University 
Skills  
Laboratory: HPLC, UPLC, AKTA, Column packing, Depth filtration, Dialysis membranes 
Software: UNICORN, OpenLAB, Empower, JMP, ELN, LIMS, MATLAB/Simulink, 
Microsoft Office Suite 
 
Work Experience  
Antibody Drug Conjugate Co-Op, Protein Purification | MedImmune | June 2017 – 
December 2017 
Increasing the efficiency of antibody drug conjugate synthesis  
Project 1: Improving the reduction & post-reduction purification method for the 
synthesis of site-specific antibody drug conjugates using DTBA and cation 
exchange displacement chromatography  
 Performed high-throughput screening for chromatographic resin optimization
 Chose top performing resins and tested the binding capacity of DTBA, mAb 
and mAb-DTBA mixtures
 Developed an assay to quantify residual DTBA levels in mAb-DTBA mixtures

Project 2: Improving the post-reduction purification method for the synthesis of site- 
specific antibody drug conjugates using column chromatography on 
microporous resins 
 Tested the binding capacity of TCEP, mAb, and mAb-TCEP solutions across 
a range of resins at multiple pH levels
 Tested the binding capacity of TCEP using a depth filter
 Achieved successful conjugation while implementing column 
chromatography method
 Demonstrated column chromatography removes as much TCEP as the 
current removal method while saving time
 
Automation Intern, Analytics | Regeneron Pharmaceuticals | June 2016 – 
August 2016 
 
Designed and tested UPLC methods to automate amino acid assays  




Conducted robustness studies to determine the most accurate and repeatable 
operating conditions  
Determined automation achieved a time savings of 3 minutes/sample 
Managed daily titer runs and reported data using LIMS 
 
Protein Engineering Researcher | Ostermeier Laboratory, JHU| January 2015 – May 
2016  
Identified glycine betaine (GB)-activated TALE colonies from a combinatorial 
library expressed in E. Coli using positive and negative selection  
Performed minimum inhibitory concentration assays on the colonies 
from selection to investigate the MIC shift for ampicillin in the presence 
and absence of GB  
Determined the relationship between the addition of multiple TALE binding 
sites and gene expression  
Evaluated the effect of GB on fluorescent protein expression 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
52 
